Abstract 608P
Background
Liver resection is the only treatment offering a chance of long-term overall survival (OS) to patients (pts) with CLM.This prospective cohort evaluates the R0/R1 resection rate in pts with predominant CLM who were treated with aflibercept (AFL)+FOLFIRI after failure of an oxaliplatin-based regimen.
Methods
All pts with predominant CLM initiating AFL (4 mg/kg q2w) + FOLFIRI per physician choice were eligible. Primary endpoint was R0/R1 resection rate. Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), OS and safety. Assuming a resection rate of 10-20% and 10% of follow-up loss, 140 patients were needed to determine R0/R1 resection rate with good precision.
Results
From July 2017 to July 2020, 136 consecutive pts with CLM [median age 65 years; 64.7% males; 28.7% right-sided; 55.1/8.1% RAS/BRAFmt; 80.1% synchronous; 46.3% extrahepatic sites and median of 4 CLM] were enrolled at 21 French sites. All pts received a prior oxaliplatin-based regimen, 77.4% prior anti-VEGF and 19.0% prior anti-EGFR agents. A median of 7 cycles of AFL+FOLFIRI was given. Overall, 16.2% of pts had R0/R1 liver resections (19.2% for liver only disease): 4/11 (36.4%) after failure of adjuvant oxaliplatin, 17/99 (17.2%) in 2nd line and 1/26 (3.8%) in 3rd line mCRC. Of 22 pts resected, 4 were judged resectable upfront, 15 potentially resectable and 3 unresectable before treatment by the investigator. Median duration of follow-up was 10.7 months (Table). Four pts (18.2%) had post-operative complications (all Dindo-Clavien grade I-II); 34.3% had grade ≥3 adverse events with AFL+FOLFIRI, mainly general health deterioration (8.0%) and diarrhoea (3.6%). Table: 608P
Secondary efficacy endpoints
All (n=136) | Resected (n=22) | Not resected (n=114) | |
Best ORR*, % | 30.1% | 68.2% | 22.8% |
Median PFS, mo [95% CI] | 5.4 [4.4-5.9] | 11.1 [5.9-13.8] | 5.1 [3.7-5.7] |
Median OS from AFL initiation, mo [95% CI] | 11.2 [9.4-14.1] | NR [20.4-NR] | 9.4 [8.2-11.2] |
Median OS from mCRC diagnosis, mo [95% CI] | 28.1 [24.1-30.8] | 55.0 [54.4-NR] | 26.5 [21.7-29.0] |
2-year OS rate from AFL initiation | 19.9% | 62.6% | 11.1% |
∗Complete + partial responses; mCRC: metastatic colorectal cancer; CI: confidence interval; mo: months; NR, not reported
Conclusions
This prospective cohort suggests that AFL+FOLFIRI allows a clinically relevant rate of conversion from potentially resectable/unresectable to resectable CLM.
Clinical trial identification
NCT00454220.
Editorial acknowledgement
Editorial assistance was provided by Nazmeen Saba at Sanofi at the direction of the authors.
Legal entity responsible for the study
Sanofi.
Funding
Sanofi.
Disclosure
R. Adam: Financial Interests, Personal, Invited Speaker, speaker at symposium: Merck Serono; Financial Interests, Personal, Invited Speaker, Speaker at symposium: Sanofi. B. Chibaudel: Financial Interests, Personal, Invited Speaker: Sanofi, Roche, Merck, Servier, Pierre Fabre, Bristol Myers Squibb, MSD, BeiGene, Lilly, Biocartis, SeqOne, Amgen, Bayer; Financial Interests, Institutional, Local PI: Sanofi. S. Kim: Financial Interests, Personal, Invited Speaker: Merck, Pfizer, Amgen, Bayer, Servier; Financial Interests, Personal, Advisory Board: MSD. J.M. Phelip: Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Advisory Board: Sanofi. M. Bouattour: Financial Interests, Personal, Advisory Board: MSD, Bristol Myers Squibb, Sirtex Medical, Ipsen, AbbVie, AstraZeneca, Servier, Taiho; Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Principal Investigator: MSD, Bristol Myers Squibb, Sirtex Medical, AstraZeneca. T. Lecomte: Financial Interests, Personal, Invited Speaker: Ipsen, Pierre Fabre, AstraZeneca, Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Sanofi, Merck Serono, Servier, Amgen, Deciphera, Advanced , Accelerator, Applications, Pierre Fabre; Financial Interests, Institutional, Local PI: AstraZeneca, Mirati, ALX Oncology; Financial Interests, Institutional, Funding: Leo Pharma, Pierre Fabre. H. Perrier: Non-Financial Interests, Principal Investigator: Roche, Amgen, Merck, Pierre Fabre, Servier, Sanofi, Bayer, Seagen. F.X. Caroli Bosc: Financial Interests, Personal, Invited Speaker: Sanofi, Pierre Fabre; Financial Interests, Personal, Advisory Board: Sanofi, Pierre Fabre. J. Metges: Non-Financial Interests, Principal Investigator: Sanofi. M. Ferec: Non-Financial Interests, Principal Investigator, Trial ASPIK (FFCD): FFCD; Financial Interests, Institutional, Local PI, Local investigator trial APICAT (APHP) on apixaban (Bristol Myers Squibb): Bristol Myers Squibb; Other, 16/09/21 congress invitation: Ipsen Pharma; Other, 02/06/22 training evening: Sandoz; Other, 21/09/22 training evening: Merck Serono. V. Hautefeuille: Financial Interests, Personal, Invited Speaker: AAA, Ipsen; Financial Interests, Personal, Advisory Board: Amgen , Deciphera, Servier , Merck, Pierre Fabre. D. Tougeron: Financial Interests, Personal, Advisory Board: AstraZeneca, Sanofi, Amgen, MSD, Roche, Servier, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
570P - Subclasses of microsatellite-instability colorectal cancer with unique molecular features and immune cell infiltration patterns
Presenter: Kui Wu
Session: Poster session 10
571P - Artificial intelligence-powered analysis of tumor lymphocytes infiltration: A translational analysis of AtezoTRIBE trial
Presenter: Martina Carullo
Session: Poster session 10
572P - Neoantigen heterogeneity among subtypes in colorectal cancer
Presenter: Fuqiang Li
Session: Poster session 10
574P - Comparative analysis of the tumor immune microenvironment (TIME) in primary and metastatic sites of microsatellite stable (MSS) and microsatellite instability-high (MSI) colorectal cancer
Presenter: Marwan Fakih
Session: Poster session 10
575P - Impact of immunological alterations and post-operative biomarkers on long-term outcomes in patients with locally advanced rectal cancer: Results from the STAR-01 study cohort
Presenter: Francesca Negri
Session: Poster session 10
576P - Prognostic values of a modified diagnostic biopsy-adapted immunoscore based on double immunohistochemical staining in patients with locally advanced rectal cancer
Presenter: Qiang Zeng
Session: Poster session 10
577P - Systematically assessing the intratissue microbiota in 937 patients with colorectal cancer
Presenter: Huanzi Zhong
Session: Poster session 10
578P - Tissue-resident microbiota characterization in colorectal cancer metastases
Presenter: Philippe Stevens
Session: Poster session 10
579P - A clinico-imaging predictive artificial intelligence model of relapse in colon cancer using baseline CT scans
Presenter: América Bueno Gómez
Session: Poster session 10